Brief: 3Sbio Inc Says NMPA Approved Clinical Trial Application For Anti-Il-5 Humanized Monoclonal Antibody Injection
25/02/2020 13:45
Feb 26 (Reuters) - 3SBio Inc 1530.HK :
* NMPA APPROVES CLINICAL TRIAL APPLICATION FOR
ANTI-INTERLEUKIN-5
(IL-5) HUMANIZED MONOCLONAL ANTIBODY INJECTION (“610”)
Source text for Eikon: urn:newsml:reuters.com:*:nHKS2p0TL9
Further company coverage: 1530.HK
(Reuters.Briefs@thomsonreuters.com)